Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis

NCT04593251 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

73

Enrollment

INDUSTRY

Sponsor class

Conditions

Eosinophilic Esophagitis
Celiac Disease

Interventions

BIOLOGICAL: CALY-002
BIOLOGICAL: Placebo

Sponsor

Calypso Biotech BV